2e1b7fa8e03c635677837a3ca93f9a3e

HEMOSIL ACUSTAR ANTI-CARDIOLIPIN IGG CONTROLS

WERFEN COLOMBIA SAS·II·Colombia INVIMA·Expires September 16, 2031

Device classification

Risk class / Clase de Riesgo: II
Product type (Spanish): REACTIVO DIAGNOSTICO
Product type (English): DIAGNOSTIC REAGENT

Registration information

Analysis ID: 2e1b7fa8e03c635677837a3ca93f9a3e
Expire date: September 16, 2031

Authorized company / Fabricante

Name (Spanish): WERFEN COLOMBIA SAS
Name (English): THROW COLOMBIA SAS

Product use / Uso del Producto

Spanish

DETERMINACIÓN DE LOS DIFERENTES ANALITOS RELACIONADOS CON MUESTRAS PROCEDENTES DEL ORGANISMO HUMANO.

English

DETERMINATION OF THE DIFFERENT ANALYTES RELATED TO SAMPLES FROM THE HUMAN ORGANISM.

About this record

Access comprehensive regulatory information for HEMOSIL ACUSTAR ANTI-CARDIOLIPIN IGG CONTROLS (HEMOSIL ACUSTAR ANTI-CARDIOLIPIN IGG CONTROLS) in the Colombia medical device market through Pure Global AI's free database. This II medical device is registered under INVIMA analysis ID 2e1b7fa8e03c635677837a3ca93f9a3e and manufactured by WERFEN COLOMBIA SAS. The device was registered on September 16, 2031.

This page provides complete registration details including product type (DIAGNOSTIC REAGENT), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.